Insights & Resources | Pfizer CentreOne

Transitioning from a Vial to PFS: What are the Benefits?

The development of parenteral drugs has increased significantly, with the market set to reach $1.2 billion USD by 2028¹.

Making the Move: Migrating a Drug Product from Vial to Prefilled Syringe

In this article we're continuing our conversation on migrating parenteral drug products from traditional glass vials to PFS devices, we’ll focus on the technical aspects of this change, discussing the analytical requirements and screening requirements that must be followed when migrating a drug p

CMO Leadership Awards 2022: Pfizer CentreOne Wins for Sixth Consecutive Year

Pfizer CentreOne wins CMO leadership awards for sixth consecutive year, learn what it means to the in this interview with Andrew Moore

Balancing Pressing Priorities

In the latest roundtable discussion with BioPharm International, our contract manufacturing lead Tom Wilson spoke alongside other industry leaders about these supply chain challenges and how we were able to change our business processes and develop best practices to ensure effective remote partne

Considerations for Migrating a Drug Product Presentation from Vial to Pre-Filled Syringe

This whitepaper outlines the benefits of PFS transfer, the differences between glass and PFS devices, and the key engineering processes required to successfully carry out this process.

Three Key CDMO Trends for 2022 and Beyond

What are the key CDMO trends pharmaceutical companies must prepare for in 2022 and beyond? This blog explains our top 3. Read more here.

Exploring best-practice manufacturing strategies for highly potent oral solid dosage forms

In this white paper Pfizer CentreOne examines what developers and their manufacturing partners need to know about its unique regulatory challenges and how to navigate HPOSD’s complex manufacturing environment successfully.

Placing Drug Strategies on a Solid Foundation for Success

Our whitepaper explores current market dynamics and the latest drug development trends driving these strategic outsourcing decisions.

Migrating A Drug Product Presentation From Vial To Prefilled Syringe - On Drug Delivery

This article explores some of the leading engineering activities that are necessary for successful PFS transfers and the benefits they offer.

Understanding the Challenges of Highly Potent Actives - International Pharmaceutical Industry

From managing health and safety risks to effective potency classifications, there are many challenges pharmaceutical companies face when using highly potent active pharmaceutical ingredients (HPAPIs) for the first time.

Pfizer CenterOne’s Enviero® receives first EU authorization as part of ESTIMA® (progesterone) product approval.

Pfizer CentreOne’s green-chemistry progesterone API, Enviero®, has been approved for use in the EU for the first time in a drug product manufactured by French pharmaceutical company, Effik.

Sterile Injectables Supply on Demand

Demand for supplies of materials for sterile injectable production, such as glass vials, filters, and stoppers has soared, which has resulted in shortages that have impacted the manufacturing of other drug products.